

Technology Advisory Interests Register

**Topic: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
[ID3949]**

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Amanda Adler	TAC Committee Member	Professional Interests	Amanda is on the executive committee of a trial run by Lilly in an unrelated disease area (cardiovascular disease) and is a different therapeutic entity being a drug for obesity. She does not get paid, her university does not get paid, and her department does not get paid.	28/01/2025	It was agreed that Amanda's declaration would not prevent them from participating in discussions on this appraisal
Adam Januszewski	Clinical Expert	Financial and Professional Interests	Adam has received honoraria from Roche for ctDNA report writing, internal Roche teaching and an advisory board. Roche paid his conference fees / attendance at ESMO 2025. He has received honoraria from MSD for Symposium teaching at BTOG 2024 and attendance to BTOG 2024. He has received honoraria from Pfizer. He has participated on a data safety monitoring board or advisory board for BMS, Pfizer, and MSD. He is also	11/07/2024	It was agreed that Adam's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			a member of the BTOG Steering Committee.		
Dr Carles Escriu	Clinical Expert	Professional Interests	Carles attended a virtual medical advisory board for UK NSCLC clinicians conducted by Regeneron in May 2024.	20/12/2024	It was agreed that Carles' declaration would not prevent them from providing expert advice to the committee